News Jiangsu Yahong Meditech Co., Ltd.

Equities

688176

CNE100005XW0

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-06-24 EDT			5-day change	1st Jan Change
5.18 ^CNY	-0.77%		-4.78%	-51.95%

06-25	Yahong Meditech to Trial Drug Against Amoebae Infection	MT
06-17	ReviR Therapeutics Reaches Milestone in Novel Splicing Therapy Development in Collaboration with Asieris Pharmaceuticals	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Yahong Meditech to Trial Drug Against Amoebae Infection	06-25	MT
ReviR Therapeutics Reaches Milestone in Novel Splicing Therapy Development in Collaboration with Asieris Pharmaceuticals	06-17	CI
Photocure ASA Partner Asieris Pharmaceuticals Announces New Drug Application Acceptance for Regulatory Review of Cevira in China	05-12	CI
Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Tranche Update on Jiangsu Yahong Meditech Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	04-01	CI
Asieris Pharmaceuticals Announces Release of Positive Results from Multicenter Phase III Global Clinical Study	03-18	CI
Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Asieris Pharmaceuticals to Unveil First-Ever Results of the International Multicenter Phase III Clinical Study for 1702, a Non-Surgical Treatment for Cervical HSIL, at the 2024 EUROGIN	02-22	CI
Jiangsu Yahong Meditech to Buy Back Shares for Up to 100 Million Yuan	02-12	MT
Jiangsu Yahong Meditech Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	02-06	CI
Jiangsu Yahong Meditech Co., Ltd. authorizes a Buyback Plan.	02-05	CI
Asieris Releases Phase III Clinical Study and Real-World Research Data for APL-1706, A Bladder Cancer Diagnosis and Management Drug, At the 2024 ASCO-GU	01-29	CI
Asieris Pharmaceuticals Announces Set-Up of the Women's Health Business Unit for Commercialization	01-08	CI
Asieris Pharmaceuticals Appoints Sophia Cao as Senior Vice President and Head of the Women's Health Business Unit	01-08	CI
Certain A Shares of Jiangsu Yahong Meditech Co., Ltd. are subject to a Lock-Up Agreement Ending on 7-JAN-2024.	01-06	CI
Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Asieris Pharmaceuticals Unveils Results of Its Hexvix[®] (Apl-1706) Phase III Clinical Trial in China	23-10-12	CI
Photocure Partner Asieris Pharmaceuticals to Present First Results for its Hexvix Phase III Clinical Trial in China at the SIU2023 Annual Meeting	23-10-07	CI
Jiangsu Yahong Meditech Completes Phase III Trial Into APL1702 Drug; Shares Drop 4%	23-09-21	MT
Asieris Pharmaceuticals Announces the First Non-Vaccine Investigational Product for Cervical HSIL Has Achieved Its Primary Endpoint	23-09-20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Jiangsu Yahong Meditech Co., Ltd.

Equities

688176

CNE100005XW0

Summary

Filters